20 results
424B3
PYXS
Pyxis Oncology Inc
30 Jun 23
Prospectus supplement
4:05pm
their future with their respective companies. These uncertainties may impair Pyxis Oncology’s and Apexigen’s ability to retain, recruit or motivate key … be detrimental to Apexigen if Apexigen cannot recruit suitable replacements in a timely manner. The competition for qualified personnel
S-4/A
qmmzfd3az mv
29 Jun 23
Registration of securities issued in business combination transactions (amended)
4:09pm
S-4
2uldv0tdu p1vq
8 Jun 23
Registration of securities issued in business combination transactions
8:03am
10-K
1h909f
29 Mar 22
Annual report
7:36am
10-Q
7uttf6haqdz7lc
15 Nov 21
Quarterly report
7:54am
424B4
qyxk2cid1zlxk
8 Oct 21
Prospectus supplement with pricing info
5:00pm
S-1
va4tt3hte43cl 1g02m
17 Sep 21
IPO registration
5:00pm
DRS/A
oq767fo2kga316hy
10 Sep 21
Draft registration statement (amended)
12:00am
DRS/A
4v4ooxoo1ml4 g1t
4 Aug 21
Draft registration statement (amended)
12:00am
DRS
0w7ffgcnotr8ji
21 Jun 21
Draft registration statement
12:00am
- Prev
- 1
- Next